Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKCA

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

Akcea Therapeutics logo

About Akcea Therapeutics Stock (NASDAQ:AKCA)

Advanced Chart

Key Stats

Today's Range
$18.17
$18.17
50-Day Range
$18.13
$18.17
52-Week Range
$8.00
$21.70
Volume
N/A
Average Volume
361,806 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AKCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKCA Stock News Headlines

Arcturus Therapeutics Holdings Inc ARCT
AKCA Historical Data
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Akcea Therapeutics Inc (AKCA)
See More Headlines

AKCA Stock Analysis - Frequently Asked Questions

Akcea Therapeutics, Inc. (NASDAQ:AKCA) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.14. The company's revenue was down 15.9% on a year-over-year basis.

Akcea Therapeutics (AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC).

Company Calendar

Last Earnings
8/04/2020
Today
7/09/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKCA
CIK
1662524
Fax
N/A
Employees
248
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$40.77 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$488.54 million
Cash Flow
$0.51 per share
Price / Cash Flow
35.54
Book Value
$5.78 per share
Price / Book
3.14

Miscellaneous

Free Float
N/A
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.45
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AKCA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners